Why is DME supplier adherence monitoring now treated as a design requirement rather than an optional feature?

CMS durable medical equipment reimbursement policy for CPAP therapy under HCPCS code E0601 requires documented patient adherence to qualify for continued coverage, which means adherence-monitoring telemetry is now a de facto commercial requirement built into device design rather than an optional add-on feature, since suppliers cannot bill for continued equipment use without that adherence data. Treating adherence monitoring as optional is a design mistake that directly undermines a product's commercial viability in the DME reimbursement model.

How does classification differ between home sleep test devices and ICU ventilators?

Home sleep test devices and standard CPAP/BiPAP systems are generally Class II devices cleared via 510(k), reflecting their lower risk profile as diagnostic or non-invasive therapy tools used largely outside a critical care setting, while ventilators span both Class II and Class III depending on their intended use and clinical setting, with more complex or life-sustaining ventilator systems facing more rigorous review. This means a single company developing both a home sleep diagnostic and a hospital ventilator can face materially different regulatory timelines and evidentiary burdens within the same broader respiratory product portfolio.

What material and component testing lesson from the Philips recall applies broadly to respiratory device design?

The core regulatory and engineering lesson was that any material with long-term patient airway or skin contact, not just sound-abatement foam, requires rigorous, long-duration off-gassing and degradation characterization under realistic use conditions, including exposure to cleaning agents and typical humidity and temperature cycles, rather than short-duration bench testing alone. Manufacturers across the respiratory device category have since expanded post-market material surveillance and pre-market material qualification protocols specifically in response to the gaps this recall exposed.

All terms

Market SegmentsStrategic Landscape

Sleep & Respiratory Devices

Devices for diagnosis and treatment of sleep-disordered breathing and chronic respiratory disease, CPAP, BiPAP, ventilators, and home sleep tests.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026

Definition

The sleep & respiratory segment covers home sleep test (HST) devices, polysomnography systems, CPAP and BiPAP/auto-titrating PAP, adaptive servo-ventilation, home and ICU ventilators, and oxygen concentrators. The June 2021 Philips Respironics recall of millions of CPAP/BiPAP devices over PE-PUR foam degradation is the largest medical-device recall in MedTech history and reshaped the segment's competitive structure.

What the regulation says

CPAP/BiPAP are Class II 510(k) under product codes BZD/MNT. Ventilators span Class II and Class III. The Philips recall was a Class I recall under 21 CFR Part 806 with a related FDA consent decree (April 2024).

What this means in practice

DME reimbursement (HCPCS E0601 for CPAP) and supplier compliance (adherence-monitoring requirements) drive product design. Adherence monitoring data is now a routine payer requirement.

Examples

A patient experiencing chronic daytime fatigue undergoes a home sleep study to diagnose potential sleep apnea, using a portable device that records breathing patterns and oxygen levels overnight.
Individuals with obstructive sleep apnea often use a positive airway pressure device nightly, which can transmit usage data directly to their healthcare provider for adherence monitoring and reimbursement purposes.
For severe respiratory conditions, patients might rely on a ventilator at home, or an oxygen concentrator to ensure adequate oxygen supply, demonstrating the range of supportive respiratory devices.

Common pitfalls

•Sourcing sound-abatement foams without long-term off-gassing characterization (the Philips lesson).
•Treating adherence data telemetry as optional, payers require it.

Frequently asked questions

The 2021 recall of millions of CPAP and BiPAP devices over PE-PUR sound-abatement foam degradation, classified as a Class I recall under 21 CFR Part 806, was the largest medical device recall in MedTech history and resulted in a 2024 FDA consent decree that continues to shape the affected manufacturer's operations and reshaped competitive dynamics across the entire sleep therapy segment. It also elevated FDA and industry scrutiny of material characterization for any component with long-term patient contact, well beyond sound-abatement foam specifically, since the underlying failure mode was inadequate off-gassing and degradation testing over the device's real-world lifespan.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Regulatory

510(k) Premarket Notification(510(k))

FDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.

Reimbursement

Durable Medical Equipment, Prosthetics, Orthotics, and Supplies(DMEPOS)

Medicare benefit category covering durable medical equipment, prosthetics, orthotics, and supplies, billed under HCPCS Level II codes through DME MACs.

Post-Market

Post-Market Surveillance(PMS)

Activities to monitor device safety and performance after market release.

Latest in MedTech

Sources

3 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 2

Link health: 3 verified· last checked 2026-06-20

FDA·1AdvaMed·1MedTech Europe·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Market Segments0 / 38

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Market Segments
Sources: 3
Updated: 5/9/2026

Compare with another term

Learn in 60 seconds

Devices for diagnosis and treatment of sleep-disordered breathing and chronic respiratory disease, CPAP, BiPAP, ventilators, and home sleep tests.

·DME reimbursement (HCPCS E0601 for CPAP) and supplier compliance (adherence-monitoring requirements) drive product design.
·Adherence monitoring data is now a routine payer requirement.

Remember this

Watch out: Sourcing sound-abatement foams without long-term off-gassing characterization (the Philips lesson).

Related terms

You may also need

Auto-suggested from Market Segments and shared keywords.

All Market Segments terms